The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season's adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4% (95% confidence interval (CI): 41.0-61.6) against influenza-confirmed primary care consultation, 54.5% (95% CI: 41.6-64.5) against influenza A(H1N1)pdm09 and 54.2% (95% CI: 33.1-68.6) against influenza B. In 2-17 year-olds, adjusted VE for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any influenza, 81.4% (95% CI: 39.6-94.3) against influenza B and 41.5% (95% CI: −8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than 65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.
Introduction
The United Kingdom (UK) has had a long-standing selective inactivated influenza vaccination programme targeted at individuals at higher risk of severe disease such as the elderly, those with an underlying clinical risk condition and pregnant women. Following recommendations from the Joint Committee of Vaccination and Immunisation (JCVI) in 2012, the decision was taken for a phased introduction of a newly licensed live attenuated influenza vaccine (LAIV), ultimately offered LAIV in each season to all healthy children aged two to 16 years [1] . 2015/16 is the third season of the introduction of this new influenza vaccination programme; all healthy children aged two to four years and in school years 1 and 2 were offered a single dose of LAIV [2] . In Northern Ireland and Scotland and in selected pilot areas in England, all other older children of primary school age were also offered LAIV in 2015/16. Children aged two to 17 years in a clinical risk group were also offered LAIV, while children with a risk factor, in whom LAIV is contraindicated, were offered quadrivalent inactivated influenza vaccine (IIV). All children in a clinical risk group aged six to 23 months were offered IIV. The United States Centers for Disease Control and Prevention (US CDC) recently reported the observation that LAIV did not provide protection in children against circulating influenza strains in North America in the 2015/16 season [3] . This raised a question about the effectiveness of LAIV in children in the UK.
In the UK, the 2015/16 season started late, peaking in week 11 of 2016, with circulation initially dominated by influenza A(H1N1)pdm09 viruses. Impact mainly fell on younger adults resulting in large numbers of hospitalisations and admissions to intensive care units (ICU) [4] . [4] . This raised questions about the protection provided by the 2015/16 trivalent vaccine, the main influenza vaccine offered to adults, and about the potential added value of switching to quadrivalent vaccine as the main vaccine of choice.
Following the mid-2015/16 season report of influenza vaccination effectiveness (VE) [5] , this article presents the end-of-season estimates of influenza VE using well established systems across the four countries of the UK [6, 7] . The aims of the investigation were to measure VE against laboratory-confirmed influenza by type, subtype and clade/lineage, and to determine the effectiveness of the vaccine in children two to 17 years of age according to type of vaccine, particularly in relation to LAIV, but also IIV. In addition, we estimated the effectiveness of both LAIV and IIV in children two to 17 years of age over the three seasons since the UK introduced the LAIV programme.
Methods

Study population and period
The test-negative case-control (TNCC) design was used to estimate VE. The study was undertaken in five sentinel general practice surveillance networks across the UK, details of which have been outlined previously [7] . The surveillance schemes were: Royal College of General Practitioners (RCGP), Research and Surveillance Centre (RSC), Specialist Microbiology Network (SMN) England and Wales, Northern Ireland and Scotland.
The main study took place from 1 October 2015 until 1 May 2016. The study population were patients presenting to their general practitioner (GP) during the study period with an acute influenza-like illness (ILI), who the physician consented verbally to be swabbed during the consultation. A patient with ILI was defined as an individual presenting in primary care with an acute respiratory illness with physician-diagnosed fever or complaint of feverishness. GPs were asked to swab a random sample of cases up to a total of 10 per week in any one practice. Cases were patients who tested positive for influenza A or B virus by real-time PCR. Controls were patients with the same symptoms who tested negative for influenza A and B. Further details of the laboratory methods are provided below.
During the consultation, the GP completed a standard questionnaire. It collected demographic, clinical and epidemiological information from patients including potential confounders such as sex, date of birth, underlying clinical risk factors, date of onset of ILI, date of sample collection (recommended within seven days of onset) and influenza vaccination history for the 2015/16 season including date of vaccination and route of administration (intranasal/injection). In England, residence in an area where a primary school LAIV immunisation programme took place was also recorded.
A further specific sub-analysis was undertaken among children two to 17 years of age for the period 1 October 2013 until 1 May 2016. This covered the period since the introduction of LAIV in the UK. All aspects of data collection, testing and analysis were comparable over this period and are as described above.
Laboratory methods
Sentinel GP surveillance networks sent the respiratory samples to the national laboratories as previously outlined [7] . Laboratory confirmation was made using comparable real-time PCR methods able to detect circulating influenza A and B viruses [8, 9] . Positive samples were sent to the reference laboratories for genetic characterisation. Isolation of influenza viruses was tried from all PCR-positive samples using MadinDarby canine kidney epithelial (MDCK) cells or MDCK cells containing the cDNA of human 2,6-sialtransferase (SIAT1) cells as described previously [10, 11] .
Antigenic characterisation was only undertaken at the PHE reference laboratory. Post-infection ferret antisera were used in haemagglutination inhibition (HI) assays with turkey red blood cells to antigenically characterise influenza A(H1N1)pdm09 and influenza B virus isolates with a haemagglutination titre ≥ 40 [12] . Reference virus strains used for HI assays for A(H1N1)pdm09 Nucleotide sequencing of the haemagglutinin (HA) gene was undertaken (primer sequences available on request) for a subset of influenza A(H1N1)pdm09 and B viruses selected to be representative of the range of the patients' age, date of sample collection, geographical location and, if performed, antigenic characterisation of the virus isolate, and phylogenetic trees were constructed with a neighbour-joining algorithm available in the Mega 6 software (http://www.megasoftware.net) [13] . The A(H1N1)pdm09 results have been previously presented [5] . HA sequences from reference strains used in the phylogenetic analysis for influenza B in this paper were obtained from GenBank: Initiative on Sharing All Influenza Data (GISAID) ( Table  1) .
Statistical methods
Patients were defined as vaccinated if they had received the 2015/16 seasonal vaccine at least 14 days before first onset of ILI. Patients were excluded if they were vaccinated less than 14 days before symptom onset. If vaccinated, but date of vaccination was unknown, the median date of vaccination of those with known dates was taken instead. Patients with date of onset not known or onset more than seven days before swabbing were also excluded. A similar approach was used to undertake a pooled analysis for the 2013/14, 2014/15 and 2015/16 seasons.
The odds ratios (OR) obtained from multivariable logistic regression models were used to calculate VE with influenza laboratory results as the outcome and influenza vaccination status as the linear predictor. Influenza A(H1N1)pdm09-and influenza B-specific VE was also calculated. Samples positive for other subtypes were excluded as the numbers were too small, except for the three-season pooled analysis, which also included influenza A(H3N2). The adjusted estimates were set based on past seasons as age (age groups: 0-4, 5-17, 18-44, 45-64, ≥ 65 years), month of sample collection, residence in area where a primary school programme was in place, sex and surveillance scheme. We also explored whether being in a risk group for whom vaccination is recommended provided any evidence of confounding. For the three-year pooled analysis, year was also included in the model. All statistical analyses were carried out in Stata version 13 (StataCorp, College Station, Texas).
The HA sequences from England obtained in this study, which were also used in the phylogenetic analysis, were deposited in GISAID under the following accession numbers : EPI679258, EPI811543, EPI811551, EPI811554,  EPI811562, EPI811570, EPI811578, EPI811586, EPI811594,  EPI811598,  EPI811606,  EPI811614,  EPI811622,  EPI811626,  EPI811629,  EPI811637,  EPI811645,  EPI811648,  EPI811656,  EPI811664,  EPI811671,  EPI811675,  EPI811683,  EPI811691,  EPI811699,  EPI811707, EPI811715, EPI811723, EPI811726, EPI811734,  EPI811742, EPI811750, EPI811758, EPI811766, EPI811774,  EPI811782,  EPI811788,  EPI811796,  EPI811799,  EPI811807, EPI811815, EPI811823, EPI811831, EPI811839,  EPI811842,  EPI811845,  EPI811853,  EPI811856,  EPI811864,  EPI811868,  EPI811876,  EPI811884,  EPI811891,  EPI811894,  EPI811898,  EPI811906,  EPI811909, EPI811915, EPI811916, EPI811924, EPI811932,  EPI811940 , EPI811944, EPI811952, EPI811958.
Results
Of the 5,811 swabbed individuals potentially eligible, 3,841 individuals were confirmed eligible and included in the study (Figure 1 ). The details of those included in the study are provided by swab result in Table 2 , including those with missing data. There were a total of 2,686 controls, 351 (9.1%) influenza B detections, 770 A(H1N1)pdm09 detections (20.0%), 24 influenza A(H3N2) detections (0.6%) and 15 influenza A(untyped) detections (0.4%). Four samples tested positive for both A(H1N1)pdm09 and influenza B and one sample was positive for both A(H1N1)pdm09 and A(H3N2). Positivity rates differed significantly by age group, sex, risk group, month, scheme, vaccination status and area of primary school programme in England (Table 2) A total of 482 influenza A(H1N1)pdm09 viruses were characterised. All belonged in the genetic subgroup 6B, which had been the predominant genetic subgroup in the 2014/15 season. Some heterogeneity was seen in the HA of the current season's A(H1N1)pdm09 viruses, with some newly emerging genetic subgroups: the HA genes of the majority (93%) of A(H1N1)pdm09 viruses fell into genetic cluster 6B.1, characterised by the amino acid changes S84N, S162N (with gain of a potential glycosylation site) and I216T, with a subset in this cluster having the substitution A215G. Less than 6% of viruses fell into a second emerging cluster (6B.2) and had the amino acid substitutions V152T, V173I, E491G and D501E in the HA gene, or into a third minor cluster with substitutions N129D, R450K and E491G. A few viruses from this season did not have any of these changes or had only the substitution S84N, and clustered with A(H1N1) pdm09 viruses from season 2014/15 (6B subgroup). A tree showing the phylogenetic relationships for the A(H1N1)pdm09 has already been published [5] . 
Model fitting for vaccine effectiveness estimation
The variables incorporated in the multivariable model (month of sample collection, age group, sex, surveillance scheme and primary school programme area) were all significantly associated with swab positivity, and all except primary school programme area and sex were confounders for the vaccine effects (changed estimates by more than 5%). As with previous seasons' analyses [5] [6] [7] , risk group was not included in the final model as it was not a confounder and data were missing for 119 samples (3.1%).
The crude and adjusted VE estimates against all confirmed influenza, influenza A(H1N1)pdm09 and influenza B for the 2015/16 season are given in Table 3 . There were inadequate numbers to estimate VE against influenza A(H3N2). The adjusted VE was 52.4% (95% confidence interval (CI): 41.0-61.6) against all laboratory-confirmed influenza for all ages. (Table 4 ). There was no significant difference in VE against influenza A(H1N1) pdm09 by time since vaccination or period of vaccination (Table 4) , overall or by age (adult/child). (Table 4) , although these agespecific differences in VE were not significant. There was no significant difference in influenza B VE by time since vaccination or by period of vaccination (Table 4 ).
The VE results by type of vaccine in children two to 17 years of age are given in Table 5 . For children receiving LAIV, the overall VE against all laboratory-confirmed influenza was 57.6% (95% CI: 25. In 2013/14, the dominant circulating strain was influenza A(H1N1)pdm09, whereas in 2014/15, the dominant circulating strain was influenza A(H3N2), which had antigenically and genetically drifted from the vaccine strain, followed by influenza B mainly of the B/ Yamagata lineage. Over the three seasons, the overall VE of LAIV was 53.1% (95% CI: 31.4-67.9) against all confirmed influenza, with a VE of 31.5% (95%CI: −50. 4-68.8) for IIV ( Table 6 ). The LAIV VE showed evidence of significant VE against laboratory-confirmed influenza B infection, borderline significance against influenza A(H3N2) and moderate, non-significant effectiveness against influenza A(H1N1)pdm09. Over the three-year period, albeit with small numbers, there was no evidence of significant effectiveness of IIV against influenza B or A(H3N2), but effectiveness of 100% (95% CI: 16.2-100) against influenza A(H1N1)pdm09.
Discussion
In the 2015/16 season, the UK completed the third season of the introduction of a universal paediatric LAIV programme. The 2015/16 season was characterised by late, prolonged influenza A(H1N1)pdm09 activity, with predominance of an emerging genetic HA subgroup, which was antigenically well matched to the vaccine strain, followed by circulation of influenza B viruses, predominantly of the B/Victoria lineage which was not represented in the 2015/16 trivalent inactivated influenza vaccine. The end-of-season VE was moderately good in adults for influenza A(H1N1)pdm09 and in adults younger than 65 years for influenza B, despite the B lineage mismatch for the trivalent influenza vaccine, the main vaccine used in adults. Overall VE for LAIV in children was also moderately good and specifically for influenza B, it was very good, although protection was less against influenza A(H1N1)pdm09. There was no evidence to suggest waning vaccine-derived protection or changes in circulating strains over the 2015/16 season.
We found an overall significant VE of 52.4% and specifically of 54.5% against influenza A(H1N1)pdm09, the dominant circulating strain this season. Although 2015/16 has seen the continued emergence of the new genetic subgroups 6B.1 and 6B.2, the antigenic characterisation indicates a good match to the 2015/16 influenza vaccine strain and no measurable differences between these two emerging groups, which reinforces the VE findings in this paper. These levels of effectiveness are consistent with those reported mid-season in 2015/16 [5] , but also in earlier A(H1N1)pdm09 seasons, in particular in 2010/11 [14] . The 2015/16 A(H1N1) pdm09 VE results were also similar to the mid-season estimates reported from North America and elsewhere in Europe this season [15, 16] . The continuing apparent antigenic and epidemiological match to the vaccine strain remains encouraging and supports the World Health Organization's recommendation that the vaccine for the 2016/17 northern hemisphere winter should include an A/California/7/2009-like vaccine strain [17] .
In younger adults under 65 years of age, influenza B VE was over 50%. Almost all vaccinated adults in the UK can be expected to have received the 2015/16 trivalent inactivated (rather than the quadrivalent) influenza vaccine, which contained the B/Yamagata vaccine strain in 2015/16. Our results indicate that despite this lineage mismatch, the 2015/16 IIV in younger adults continued to provide important levels of protection against influenza B, findings which are consistent with earlier published literature [18] . On the other hand, we failed to find evidence of significant VE against influenza B in the elderly, although underpowered with only 19 positive detections and a low positivity of 4.6% in this age group. This is in contrast to the 2014/15 season, when influenza vaccines elsewhere in Europe provided effectiveness of 50.4% (95% CI: 14.6-71.2) against influenza B in those older than 65 years [19] ; in that season, the dominant circulating strain was B/ Yamagata and belonged to a clade that was antigenically similar to the vaccine virus that season. Evidence of cross-protection, as we seem to have seen in the younger adults this season, might have important implications for the potential incremental cost-effectiveness and recommendations for preferential use of quadrivalent vaccines in adults and highlights the importance of gathering further data in this area to better inform such decisions. 2-17 60.6 (34.4-76.3) 48.5 (8.5-71.0) 76. 5 (41.9-90.5) 18-44 55.3 (34.2-69.6) 59. 8 (35.8-74.8) 45.9 (1.0-70.4) 45-64 55. 4 (34.6-69.5) 58. 6 (36.9-72.8) Among children two to 17 years of age, we observed an overall significant VE of 57.6% for the quadrivalent LAIV vaccine this season, specifically 81.4% for influenza B and 41.5% for influenza A(H1N1)pdm09, with a similar picture when examining the previous three seasons. Over the three seasons, the overall effectiveness of LAIV was higher compared with inactivated vaccine in that age group, specifically for influenza A(H3N2) and B, but lower in 2015/16 and specifically for influenza A(H1N1)pdm09. These findings are in contrast to those recently reported by the US CDC who found an overall VE of only 3% for LAIV in two to 17 year-old children with very low VE against influenza A(H1N1)pdm09, while the inactivated vaccine showed significant effectiveness [3] . The US first noted lower VE of LAIV against influenza A(H1N1)pdm09 in 2013/14, which on further investigation was considered related to reduced thermostability of the A/California/7/2009 vaccine strain [20] . This led to the replacement of the A(H1N1)pdm09 LAIV vaccine strain with the more recently emerged A/ Bolivia/559/2013 vaccine strain for the 2015/16 season. Based on the 2015/16 VE findings from the CDC, the US Advisory Committee on Immunisation recommended a temporary suspension of use of LAIV for children in the US for the forthcoming 2016/17 season [3] . In addition to the UK findings presented here, Finland, in its first season of use of LAIV in pre-school age children, found overall levels of protection of 51%, similar to the UK [21] .
The reasons why the observed levels of overall protection were higher in Europe than in the US, with apparent reduced protection against influenza A(H1N1) pdm09 compared to IIV, remain under investigation. Several hypotheses have been suggested. Firstly, are the observed differences real or the consequence of a methodological difference? If real, viral interference between the A(H1N1)pdm09 vaccine strain and the other influenza vaccine viruses in the quadrivalent LAIV vaccine might provide an explanation; such interference has been discussed previously [22] and might be reinforced by prior vaccination with LAIV and/or IIV in young children (which is at present much more likely in North America than Europe) or by repeat vaccination in-season, with the US offering two doses of influenza vaccine to children compared with one dose for healthy children in Europe. A further explanation is possible antigenic drift between the A/Bolivia/559/2013 vaccine strain in the 2015/16 LAIV vaccine and circulating A(H1N1)pdm09 strains in winter 2015/16, although antigenically, the virus is considered to be well matched. Finally, programmatic or logistical differences, e.g. related to cold chain or vaccine handling might play a role.
Further work is required to investigate these hypotheses, although UK programme evaluation results from 2013/14 and 2014/15 already suggest that the UK LAIV paediatric programme reduced influenza circulation when comparing pilot areas where children of primary school age were offered vaccine to those areas where they were not [23, 24] . The UK VE results presented in this paper have been reviewed by the JCVI who strongly recommended not to change the current influenza immunisation strategy planned for 2016/17, but further work is required to better understand these recent observations in the light of the US findings and to potentially optimise vaccine composition.
Although waning protection post vaccination has recently been noted [25] and although 2015/16 was a particularly late influenza season with significant activity until late into the spring, there was no evidence to suggest either waning protection by time since vaccination or changes in effectiveness by vaccination period due to the emergence of new clades or lineages over the course of the season in the UK. Our findings are congruent with recent work which suggests that intra-seasonal waning is of lesser importance with influenza A(H1N1)pdm09 and influenza B compared with influenza A(H3N2) [25] .
The paper has a number of strengths. It uses a wellestablished methodology, the TNCC, the results of which approximate well to more traditional case-control approaches [26] . Data completeness was very high and the integration of genetic characterisation data has allowed the estimation of clade-and lineage-specific VE. Caution is needed in the interpretation of the results in children two to 17 years of age owing to the small sample size, particularly in relation to IIV where only a small proportion of the paediatric control population with available information (16/507, 3%) were reported to be vaccinated, while for LAIV, 18% of controls were reported vaccinated.
Conclusion
In summary, notwithstanding the limitation of the small sample size, our findings together with those from Finland confirm encouraging overall levels of protection for LAIV. This protection is particularly effective against influenza B, though less against influenza A(H1N1)pdm09, a finding which in the light of observations in the US requires further investigation. 
